Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes

Standard

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes : A Slope Analysis from the EMPA-REG OUTCOME Trial. / EMPA-REG OUTCOME Investigators.

In: Journal of the American Society of Nephrology : JASN, Vol. 29, No. 11, 11.2018, p. 2755-2769.

Research output: Contribution to journal › Article › peer-review

Author

EMPA-REG OUTCOME Investigators. / Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes : A Slope Analysis from the EMPA-REG OUTCOME Trial. In: Journal of the American Society of Nephrology : JASN. 2018 ; Vol. 29, No. 11. pp. 2755-2769.

BibTeX

@article{71a1d496281348759c27d6336e14de98,

title = "Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial",

abstract = "Background Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes.Methods Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up).Results Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m(2)) decreased with empagliflozin (-0.77; 95% confidence interval, -0.83 to -0.71; placebo: 0.01; 95% confidence interval, -0.08 to 0.10; PConclusions The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.",

keywords = "chronic kidney disease, diabetes mellitus, randomized controlled trials, ESTABLISHED CARDIOVASCULAR-DISEASE, GLOMERULAR-FILTRATION-RATE, COTRANSPORTER 2 INHIBITION, GFR DECLINE, END-POINTS, MECHANISMS, MELLITUS, SAFETY",

author = "{EMPA-REG OUTCOME Trial} and Christoph Wanner and Heerspink, {Hiddo J. L.} and Bernard Zinman and Inzucchi, {Silvio E.} and Audrey Koitka-Weber and Michaela Mattheus and Stefan Hantel and Hans-Juergen Woerle and Broedl, {Uli C.} and {von Eynatten}, Maximilian and Per-Henrik Groop and D. Aizenberg and M. Ulla and J. Waitman and {De Loredo}, L. and J. Farias and H. Fideleff and M. Lagrutta and N. Maldonado and H. Colombo and {Ferre Pacora}, F. and A. Wasserman and L. Maffei and R. Lehman and J. Selvanayagam and M. d'Emden and P. Fasching and B. Paulweber and H. Toplak and A. Luger and H. Drexel and R. Prager and A. Tiburcio and S. Gupta and S. Park and Y. Kim and J. Yang and D. Kim and S. Lee and A. Petrov and K. Nikolaev and V. Potemkin and A. Bystrova and N. Tarasov and A. Obrezan and A. Khokhlov and C. Huang and J. Chen and J. Wang and S. Zotov",

year = "2018",

month = nov,

doi = "10.1681/ASN.2018010103",

language = "Английский",

volume = "29",

pages = "2755--2769",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "American Society of Nephrology",

number = "11",

}

RIS

TY - JOUR

T1 - Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes

T2 - A Slope Analysis from the EMPA-REG OUTCOME Trial

AU - EMPA-REG OUTCOME Trial

AU - Wanner, Christoph

AU - Heerspink, Hiddo J. L.

AU - Zinman, Bernard

AU - Inzucchi, Silvio E.

AU - Koitka-Weber, Audrey

AU - Mattheus, Michaela

AU - Hantel, Stefan

AU - Woerle, Hans-Juergen

AU - Broedl, Uli C.

AU - von Eynatten, Maximilian

AU - Groop, Per-Henrik

AU - Aizenberg, D.

AU - Ulla, M.

AU - Waitman, J.

AU - De Loredo, L.

AU - Farias, J.

AU - Fideleff, H.

AU - Lagrutta, M.

AU - Maldonado, N.

AU - Colombo, H.

AU - Ferre Pacora, F.

AU - Wasserman, A.

AU - Maffei, L.

AU - Lehman, R.

AU - Selvanayagam, J.

AU - d'Emden, M.

AU - Fasching, P.

AU - Paulweber, B.

AU - Toplak, H.

AU - Luger, A.

AU - Drexel, H.

AU - Prager, R.

AU - Tiburcio, A.

AU - Gupta, S.

AU - Park, S.

AU - Kim, Y.

AU - Yang, J.

AU - Kim, D.

AU - Lee, S.

AU - Petrov, A.

AU - Nikolaev, K.

AU - Potemkin, V.

AU - Bystrova, A.

AU - Tarasov, N.

AU - Obrezan, A.

AU - Khokhlov, A.

AU - Huang, C.

AU - Chen, J.

AU - Wang, J.

AU - Zotov, S.

PY - 2018/11

Y1 - 2018/11

N2 - Background Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes.Methods Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up).Results Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m(2)) decreased with empagliflozin (-0.77; 95% confidence interval, -0.83 to -0.71; placebo: 0.01; 95% confidence interval, -0.08 to 0.10; PConclusions The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.

AB - Background Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes.Methods Participants (n=7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up).Results Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m(2)) decreased with empagliflozin (-0.77; 95% confidence interval, -0.83 to -0.71; placebo: 0.01; 95% confidence interval, -0.08 to 0.10; PConclusions The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.

KW - chronic kidney disease

KW - diabetes mellitus

KW - randomized controlled trials

KW - ESTABLISHED CARDIOVASCULAR-DISEASE

KW - GLOMERULAR-FILTRATION-RATE

KW - COTRANSPORTER 2 INHIBITION

KW - GFR DECLINE

KW - END-POINTS

KW - MECHANISMS

KW - MELLITUS

KW - SAFETY

U2 - 10.1681/ASN.2018010103

DO - 10.1681/ASN.2018010103

M3 - статья

VL - 29

SP - 2755

EP - 2769

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 11

ER -

ID: 87875422